Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 percent after the bell.
Marriott International Inc on Thursday missed Wall Street estimates for quarterly revenue and forecast a lower-than-expected full-year profit, blaming weak demand in North America, its largest market.
Medtronic Plc beat analysts' estimates for quarterly profit on Tuesday, boosted by sales of its surgical products, and the largest U.S. standalone medical device maker raised the upper end of its full-year earnings forecast.
Merck & Co's cancer immumotherapy Keytruda compiled sales that topped $2 billion in a quarter for the first time, exceeding Wall Street's lofty estimates and sending shares up more that 3 percent on Friday.
Walgreens Boots Alliance Inc said on Thursday it would consolidate warehouses and shut some stores as part of a cost-cutting plan aimed at saving more than $1 billion annually.
Shares of U.S. health insurers, hospitals and healthcare companies fell on Monday in the aftermath of a ruling by a federal judge in Texas that the Affordable Care Act (ACA), commonly called Obamacare, was unconstitutional.
Dec 6 Supernus Pharmaceuticals Inc's
treatment for attention deficit hyperactivity disorder met the
main goal of two trials, but shares fell about 16 percent on
Thursday as the data failed to convince some investors that the
drug was better than rivals.
A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.